The integration of mass cytometry with high-throughput drug screening has revolutionized the process of drug discovery and development, offering unprecedented insights into cellular responses to therapeutic compounds at the single-cell level. This chapter explores the applications of mass cytometry in drug screening, its impact on personalized medicine, and its adoption by pharmaceutical companies, including some intriguing developments from unexpected players in the field.
Single-cell Drug Response Profiling
Mass cytometry’s ability to simultaneously measure multiple cellular parameters has transformed our understanding of drug responses at the single-cell level.
Lun et al. (2019) published a landmark study in Molecular Cell, demonstrating the power of mass cytometry in analyzing the human kinome and phosphatome. Their work revealed how overexpression of specific kinases and phosphatases affects cancer-related signaling pathways, providing crucial insights for targeted therapy development.
Building on this foundation, Larsen et al. (2021) introduced a method for high-throughput, single-cell drug screening using mass cytometry in their Cell Reports paper, “A pan-cancer organoid platform for precision medicine”, seen as the bridge between simultaneous testing of multiple drugs on patient-derived organoïds, personalized medicine and high througput screening.
Restricted content
You must be logged in and have a valid subscription to see this content. Please visit our subscription page for more info. If you are already a VIP member, be sure you are logged in with the same email address you made your purchase.
